Table 2. Study results and adverse events.
| Study, year | Technical success | Clinical success | AEs | Severe AE | Recurrence or re-intervention | Procedure Time (min) | LOS (days) | Follow up period (days) | ||||||||
| EUS-GE | SGE | EUS-GE | SGE | EUS-GE | SGE | EUS-GE | SGE | EUS-GE | SGE | EUS-GE | SGE | EUS-GE | SGE | EUS-GE | SGE | |
| Perez-Miranda, 2017 | 22/25 | 29/29 | 21/22 | 28/29 | 3/25 | 12/29 | 1/25 | 2/29 | NR | NR | 77/66 1 | 178/66 1 | 9.4/5.7 1 | 8.9/5.7 1 | Mean 56 | Mean 268.8 |
| Khashab, 2017 | 26/30 | 63/63 | 26/26 | 57/63 | 5/30 | 16/63 | 3/30 | 0/63 | 1/26 | 9/63 | NR | NR | 11.6/6.6 1 | 12/8.2 1 | Mean/SD 115 (63) | Mean/SD 196 (155) |
| Widmer, 2019 (abs) | 10/10 | 14/14 | 10/10 | 8/14 | 0/10 | 4/14 | NR | NR | 1/10 | 0/14 | NR | NR | 4.7/1.9 | 6/3.5 | Mean/range 90 (30–180) | Mean/range 240 (30–1050) |
| Marya, 2020 (abs) | 168/172 | 39/39 | 167/168 | 32/39 | 8/172 | 7/39 | 3/172 | 0/39 | 3/168 | 5/39 | NR | NR | NR | NR | Median 234 | Median 235 |
| Bondi, 2020 (abs) | 17/18 | 34/34 | 17/17 | 33/34 | 4/18 | 16/34 | NR | NR | 6/17 | 12/34 | NR | NR | 10/10 | 13/8 | NR | NR |
| Kouanda, 2021 | 37/40 | 26/26 | 34/37 | 22/26 | 9/40 | 23/26 | NR | NR | 8/37 | 5/26 | 57.0/14.6 | 227.5/55.5 | 4.7/3.8 1 | 13.5/7.8 1 | Median/IQR 98.0 (35.5–288.5) | Median/IQR 166.5 (74–728) |
| Bronswijk, 2021 | 73/77 | 48/48 | 71/73 | 42/48 | 5/77 | 15/48 | 2/77 | 9/48 | 0/73 | 3/48 | 56/33 1 | 96/33 1 | 5.6/6.4 1 | 11.2/11.5 1 | Median/IQR 76 (36–136) | Median/IQR 122 (35–274) |
AE, adverse events; EUS-GE, endoscopic ultrasound-guided gastroenterostomy; LOS, post-procedure length of hospital stay; NR, not reported; SGE, surgical gastroenterostomy.
1
imputed values using Cochrane RevMan calculator [38,39].